RARE Daily

CureDuchenne Invests $1 Million in Gennao Bio to Accelerate DMD Research

December 23, 2021

CureDuchenne Ventures, a subsidiary of CureDuchenne, said it made a $1 million investment in Gennao Bio as part of Gennao Bio’s series A extension to fund the company’s application of its gene monoclonal antibody (GMAB) platform technology to Duchenne muscular dystrophy (DMD) and other rare muscle diseases.

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes.

Gennao’s GMAB platform technology can be used to efficiently deliver a broad range of nucleic acid payloads, including mRNA, DNA, siRNA and ASOs. The technology targets the nucleoside transporter ENT2, which is highly expressed on skeletal muscle cells thereby allowing for systemic administration and targeted delivery.

This non-viral delivery platform has the potential to overcome limitations of traditional gene delivery systems as it avoids issues with pre-existing antibodies and size limitations of viruses, allows for repeat dosing, and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology, and now with this investment, a significant focus on rare muscle diseases, including DMD.

“Through CureDuchenne Ventures, it is our mission to help accelerate scientific breakthroughs and this investment represents the next generation of potentially groundbreaking research to put an end to this devastating disease,” said Debra Miller, president of CureDuchenne Ventures and founder and chief executive officer of CureDuchenne.

Author: Rare Daily Staff

Stay Connected

Sign up for updates straight to your inbox.